Samuel B. Guze Professor of Psychiatry
- Phone: 314-747-2680
- Email: email@example.com
Additional Titles & Roles
- Head of the Department of Psychiatry
- Director, Taylor Family Institute for Innovative Psychiatric Research
- Chair, Center for Brain Research in Mood Disorders
Education & Training
- Residency: Washington University, St. Louis, MO, 1982
- MD: Washington University, St. Louis, MO, 1978
- BA: Saint Louis University, St. Louis, MO, 1974
- Listed in America’s Top Doctors, Castle Connolly Medical Ltd, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019
- Listed in Best Doctors in America (Best Doctors, Inc), 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019
- NIMH Board of Scientific Counselors (Intramural Program), 2009, 2010, 2011, 2012, 2013
- Institute of Medicine, Forum on Neuroscience, 2009, 2010, 2011, 2012, 2013, 2014
- National Academy of Medicine (Institute of Medicine), National Academy of Sciences, 2012
Areas of Clinical Interest
Brain Stimulation Methods
Treatment refractory depression
Our laboratory is interested in physiology and pharmacology of amino acid neurotransmitters with emphasis on the regulation of responses at glutamate and GABA receptors. In our studies we use a variety of methods to examine modulation of the N-methyl-D-aspartate (NMDA) and AMPA/kainate classes of glutamate receptors. We are also examining the role of glutamate reeptors in synaptic transmission and long-term potentiation in the hippocampus. Other studies are directed at understanding the modulation of GABA and glutamate receptors by neurosteroids and oxysterols. Our clinical studies are examining the benefits and risks of electroconvulsive therapy (ECT) in various groups of patients with psychiatric disorders, including the use of ECT as a maintenance therapy.
Special Populations, Data Sets and Facilities
Facilities are available for preparing in vitro hippocampal cell cultures and hippocampal slices. Equipment for intra- and extracellular electrophysiological recording from cultured cells, tissue slices or living animals.
- Paul SM, Doherty JJ, Robichaud AJ, Belfort GM, Chow BY, Hammond RS, Crawford DC, Linsenbardt AJ, Shu HJ, Izumi Y, Mennerick SJ, Zorumski CF (2013 Oct 30). The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-D-aspartate receptors. J Neurosci. 33(44): 17290-300.
Read publication »The Major Brain Cholesterol Metabolite 24(S)-Hydroxycholesterol Is a Potent Allosteric Modulator of N-Methyl-d-Aspartate Receptors
- Sun M-Y,Izumi Y,Benz A, Zorumski CF, Mennerick S, (2015 Dec) Endogenous 24S-hydroxycholesterol modulates NMDAR-mediated function in hippocampal slices. J Neurophysiology 23;115:1263-72;
Read publication »Endogenous 24S-hydroxycholesterol modulates NMDAR-mediated function in hippocampal slices.
- Zorumski CF, Izumi Y, Mennerick S: Ketamine: NMDA receptors and beyond. Journal of Neuroscience 2016; 36: 11158-11166.
Read publication »Ketamine: NMDA Receptors and Beyond
- Warikoo N, Brunwasser S, Benz AM, Shu H-J, Paul S, Lewis M, Doherty J, Quirk M, Piccio L, Zorumski CF, Day G, Mennerick S: Positive allosteric modulation as a potential therapeutic strategy in anti-NMDA receptor encephalitis. Journal of Neuroscience 2018; 38: 3218-3229.
- Izumi Y, Zorumski CF: Temperoammonic stimulation depotentiates Schaffer collateral LTP via p38 MAP kinase downstream of adenosine A1 receptors. Journal of Neuroscience 2019; 39: 1783-1792.
Read publication »Temperoammonic Stimulation Depotentiates Schaffer Collateral LTP via p38 MAPK Downstream of Adenosine A1 Receptors
- Gunduz-Bruce H, Silber C, Kaul I, Rothschild AJ, Riesenberg R, Sankoh AJ, Li H, Lasser R, Zorumski CF, Rubinow DR, Paul SM, Jonas J, Doherty JJ, Kanes SJ: Trial of SGE-217 in patients with major depressive disorder. New England Journal of Medicine (in press).
Funded Research Projects
NIMH(co-PI):Oxysterols and NMDAR Function
NIMH: Neurosteroids & Proximal Inhibition in the Hippocampus